Puerto Rico: Budget Office Prices Terminal-Only Cannabis Bill at $53m
Puerto Rico's budget office says a bill limiting medical cannabis to terminal patients would cost $53 million a year and remove 95% of patients.
On 12 October 2026, the price tag landed on a bill that would cut Puerto Rico’s medical cannabis program down to one for the dying. The island’s legislative budget office puts the cost at roughly $53 million a year, and the committee vote that decides whether the bill advances is set for 13 October.
The measure is House Bill 1281 (P. de la C. 1281), filed on 15 May 2026. It amends fourteen articles of Act 42-2017, the statute behind Puerto Rico’s medical market, and limits eligibility to people with a certified terminal medical condition or a debilitating condition directly associated with one. It also removes the separate licence physicians now need before they can recommend cannabis, opening that to any doctor already authorized to prescribe.
What changed
The Oficina de Presupuesto de la Asamblea Legislativa published Informe 2027-107 in October 2026. The office is careful about what its own number is: a static, upper-bound estimate that assumes the program’s economic and tax activity ends. It carries no position on the bill.
The estimate rests on roughly 95 percent of patients falling outside the new test, and that figure comes from the regulator’s registry, not from modelling. The Junta Reglamentadora del Cannabis Medicinal reported 259,932 condition registrations in fiscal 2025, of which 5,598 sit in the categories closest to the bill’s test: palliative care, cancer, ALS, AIDS, Parkinson’s, and Alzheimer’s. Measured against 112,223 active patients, that is about 5 in every 100.
The $53 million splits into $23.8 million of sales tax on dispensary purchases, $15.5 million in income tax, $7.1 million in licence revenue, $6 million of sales tax on what program workers spend, and $600,000 in inventory tax. Two statutory earmarks fall with it: about $2.2 million a year for the Río Piedras Medical Center trauma hospital and about $3.9 million for the catastrophic illness fund. For scale, the budget office counts 363 active dispensaries and $206.53 million in sales in fiscal 2025, and the board counted 2,326 people on program payrolls.
What This Means
For travelers, the route at risk is the non-resident one. Act 42-2017 lets a patient living in another US state qualify here on a physician’s recommendation plus a home-state ID, which is the mechanism that lets a home-state card work here for up to 30 days. House Bill 1281 keeps that route and narrows what qualifies for it. A visitor whose card was issued for chronic pain, migraines, or PTSD would sit outside the new test, and those are the conditions carrying most of the registry: the Senate’s own review in July put chronic pain alone at a third of active patients. If you are planning a trip around a dispensary visit, nothing has moved yet. Plan on the current rules through this winter and check before you fly after that.
The next real date is 13 October. The Government Commission has House Bill 1281 down for an executive meeting at 9:00 a.m. on 13 October 2026, after the Health Commission released the measure in August. What to watch is whether a committee report issues and whether it keeps the terminal-condition test intact, because the number OPAL published is tied to that clause rather than to the rest of the bill.
Source: www.opal.pr.gov
Planning a trip? Read our full guide to the current cannabis laws in Puerto Rico: what visitors can buy, carry, and where it is allowed.